Presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson's disease: A double‐tracer positron emission tomography study
暂无分享,去创建一个
Hiroyuki Okada | Toshihiko Kanno | Yasuomi Ouchi | Shuji Nobezawa | Etsuji Yoshikawa | Masami Futatsubashi | Tatsuo Torizuka | E. Yoshikawa | Y. Ouchi | S. Nobezawa | H. Okada | T. Kanno | M. Futatsubashi | T. Torizuka | M. Sakamoto | Masanobu Sakamoto
[1] S H Snyder,et al. Positron emission tomographic imaging of the dopamine transporter with 11C‐WIN 35,428 reveals marked declines in mild Parkinson's disease , 1993, Annals of neurology.
[2] S. Kish,et al. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. , 1988, The New England journal of medicine.
[3] D L Price,et al. Aminergic systems in Alzheimer's disease and Parkinson's disease , 1987, Annals of neurology.
[4] J. Lichtman,et al. Alterations in Synaptic Strength Preceding Axon Withdrawal , 1997, Science.
[5] J. Palacios,et al. Mapping dopamine receptors in the human brain. , 1988, Journal of neural transmission. Supplementum.
[6] K. Någren,et al. Striatal uptake of the dopamine reuptake ligand [11C]β-CFT is reduced in Alzheimer's disease assessed by positron emission tomography , 1998, Neurology.
[7] T Jones,et al. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. , 1990, Archives of neurology.
[8] G. Paxinos,et al. Atlas of the Human Brain , 2000 .
[9] Haruhiko Akiyama,et al. Rate of cell death in parkinsonism indicates active neuropathological process , 1988, Annals of neurology.
[10] M. Iyo,et al. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET , 1997, Nature.
[11] Y. Agid,et al. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease , 1983, Brain Research.
[12] Wade K. Smith,et al. Midbrain dopaminergic cell loss in parkinson's disease: Computer visualization , 1989, Annals of neurology.
[13] M. Endo,et al. Development of a high resolution PET , 1990 .
[14] H Okada,et al. Altered glucose metabolism in the hippocampal head in memory impairment , 1998, Neurology.
[15] R S Frackowiak,et al. Asymmetrical pre-synaptic and post-synpatic changes in the striatal dopamine projection in dopa naïve parkinsonism. Diagnostic implications of the D2 receptor status. , 1993, Brain : a journal of neurology.
[16] David J. Schlyer,et al. Graphical Analysis of Reversible Radioligand Binding from Time—Activity Measurements Applied to [N-11C-Methyl]-(−)-Cocaine PET Studies in Human Subjects , 1990, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[17] G. Pearlson,et al. Structural evaluation of the prefrontal cortex in schizophrenia. , 1998, The American journal of psychiatry.
[18] D. J. Brooks,et al. In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias , 1997, Neurology.
[19] N. Volkow,et al. Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[20] P. C. Murphy,et al. Cerebral Cortex , 2017, Cerebral Cortex.
[21] Monique Ernst,et al. DOPA Decarboxylase Activity in Attention Deficit Hyperactivity Disorder Adults. A [Fluorine-18]Fluorodopa Positron Emission Tomographic Study , 1998, The Journal of Neuroscience.
[22] Y Tateno,et al. Dopamine D1 receptors in Parkinson's disease and striatonigral degeneration: a positron emission tomography study. , 1993, Journal of neurology, neurosurgery, and psychiatry.
[23] B. Långström,et al. In vivo evaluation of striatal dopamine reuptake sites using 11C‐nomifensine and positron emission tomography , 1987, Acta neurologica Scandinavica.
[24] T. Gasser,et al. 123I‐iodobenzamide‐SPECT predicts dopaminergic responsiveness in patients with de novo parkinsonism , 1992, Neurology.
[25] Michael J. Bannon,et al. Age‐related and regional differences in dopamine transporter mRNA expression in human midbrain , 1997, Neurology.
[26] D E Kuhl,et al. Compartmental Analysis of [11C]Flumazenil Kinetics for the Estimation of Ligand Transport Rate and Receptor Distribution Using Positron Emission Tomography , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[27] D. Wong,et al. In vivo imaging of baboon and human dopamine transporters by positron emission tomography using [11C]WIN 35,428 , 1993, Synapse.
[28] Y. Agid,et al. Dopamine deficiency in the cerebral cortex in Parkinson disease , 1982, Neurology.
[29] A. Antonini,et al. [11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease , 1994, Neurology.
[30] N. Volkow,et al. Parallel loss of presynaptic and postsynaptic dopamine markers in normal aging , 1998, Annals of neurology.
[31] Y Agid,et al. Is the mesocortical dopaminergic system involved in Parkinson disease? , 1980, Neurology.
[32] L. Bäckman,et al. Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes. , 1997, Brain : a journal of neurology.
[33] D L Price,et al. Parkinson's disease , 1985, Neurology.
[34] N. Ogawa. Early introduction of dopamine agonists in the long-term treatment of Parkinson's disease , 1998, Neurology.
[35] R. Oades,et al. Ventral tegmental (A10) system: neurobiology. 1. Anatomy and connectivity , 1987, Brain Research Reviews.
[36] J. Palacios,et al. Dopamine receptors in human brain: autoradiographic distribution of D1 and D2 sites in Parkinson syndrome of different etiology , 1989, Brain Research.
[37] S. Gilman,et al. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging , 1996, Annals of neurology.
[38] A. Parent,et al. Dopaminergic innervation of the basal ganglia in the squirrel monkey as revealed by tyrosine hydroxylase immunohistochemistry , 1989, The Journal of comparative neurology.
[39] J. Rinne,et al. Positron emission tomography demonstrates dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson's disease , 1990, Movement disorders : official journal of the Movement Disorder Society.
[40] C. Patlak,et al. Nigrostriatal function in humans studied with positron emission tomography , 1989, Annals of neurology.
[41] M. Mintun,et al. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography , 1984, Annals of neurology.
[42] Y. Agid,et al. D1 and D2-type dopamine receptors in patients with Parkinson's disease and progressive supranuclear palsy , 1988, Journal of the Neurological Sciences.
[43] M. Poo,et al. Propagation of activity-dependent synaptic depression in simple neural networks , 1997, Nature.
[44] A. Lang,et al. Striatal dopamine distribution in Parkinsonian patients during life , 1985, Journal of the Neurological Sciences.
[45] P. Goldman-Rakic,et al. Brainstem innervation of prefrontal and anterior cingulate cortex in the rhesus monkey revealed by retrograde transport of HRP , 1982, The Journal of comparative neurology.